Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ONCY 
Oncolytics Biotech Inc (ONCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/08/2025: ONCY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.04
1 Year Target Price $4.04
| 1 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.52% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 88.58M USD | Price to earnings Ratio - | 1Y Target Price 4.04 |
Price to earnings Ratio - | 1Y Target Price 4.04 | ||
Volume (30-day avg) 6 | Beta 1.48 | 52 Weeks Range 0.33 - 1.53 | Updated Date 08/8/2025 |
52 Weeks Range 0.33 - 1.53 | Updated Date 08/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.0885 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -76.34% | Return on Equity (TTM) -213.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78172761 | Price to Sales(TTM) - |
Enterprise Value 78172761 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.79 | Shares Outstanding 96602000 | Shares Floating 87248310 |
Shares Outstanding 96602000 | Shares Floating 87248310 | ||
Percent Insiders 3.58 | Percent Institutions 1.55 |
Upturn AI SWOT
Oncolytics Biotech Inc
Company Overview
History and Background
Oncolytics Biotech Inc. is a biopharmaceutical company focused on the development and commercialization of oncolytic viruses as potential cancer therapeutics. It was founded in 1998. Its primary focus is on its oncolytic virus technology, Pelareorep, and its potential to treat a variety of cancers. Over time, the company has advanced Pelareorep through various clinical trials.
Core Business Areas
- Pharmaceutical Development: Focused on researching and developing oncolytic viruses, specifically Pelareorep, for cancer treatment. This includes preclinical research, clinical trials, and regulatory activities.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of Pelareorep in combination with other therapies for various types of cancer.
- Partnerships and Licensing: Seeking partnerships and licensing agreements with other pharmaceutical companies to expand the development and commercialization of Pelareorep.
Leadership and Structure
Oncolytics Biotech Inc. has a management team led by its President and CEO. The company has a Board of Directors overseeing the strategic direction. The structure includes departments focused on research and development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Pelareorep: Pelareorep is Oncolytics Biotech Inc's primary drug candidate, an oncolytic reovirus being evaluated in clinical trials for various cancer types. Market share data is not directly available as it's still in clinical development. Potential competitors include other companies developing oncolytic viruses such as Amgen (T-VEC), Replimune (RP1), and BioNTech (oncolytic virus programs).
Market Dynamics
Industry Overview
The oncolytic virus therapy market is experiencing growth due to the potential to selectively target and destroy cancer cells while stimulating an immune response. Advances in biotechnology and increased research funding are driving this market.
Positioning
Oncolytics Biotech Inc. is positioned as a clinical-stage company focusing on oncolytic virus therapies, specifically Pelareorep. Its competitive advantage lies in its unique reovirus platform and clinical trial results.
Total Addressable Market (TAM)
The total addressable market for oncolytic virus therapies is projected to reach billions of dollars annually, depending on the successful approval and adoption of such therapies for various cancer indications. Oncolytics Biotech Inc. aims to capture a significant portion of this market with Pelareorep, if approved.
Upturn SWOT Analysis
Strengths
- Proprietary reovirus platform (Pelareorep)
- Clinical trial data showing potential efficacy
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single drug candidate (Pelareorep)
- High cash burn rate
- Dependence on clinical trial success
- Limited commercialization experience
Opportunities
- Potential for FDA approval of Pelareorep
- Expansion into new cancer indications
- Strategic partnerships with larger pharmaceutical companies
- Growing market for oncolytic virus therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other oncolytic virus therapies
- Market acceptance of oncolytic virus therapies
Competitors and Market Share
Key Competitors
- AMGN
- RPIM
- BNTX
Competitive Landscape
Oncolytics Biotech Inc. faces competition from larger pharmaceutical companies with greater resources. Its advantages include its unique reovirus platform and clinical trial data. Its disadvantages include its smaller size and limited commercialization experience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by clinical development progress rather than revenue generation, as the company awaits potential drug approvals.
Future Projections: Future projections depend on the success of clinical trials and regulatory approvals. Analyst estimates are available from financial data providers.
Recent Initiatives: Recent initiatives include advancing clinical trials for Pelareorep in combination with other cancer therapies and seeking strategic partnerships.
Summary
Oncolytics Biotech Inc. is a clinical-stage company with potential in the oncolytic virus therapy space. Their primary strength is their Pelareorep drug candidate and clinical trial progress. However, they face challenges related to funding, regulatory approvals, and competition. Successful clinical trials and strategic partnerships will be crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news sources
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oncolytics Biotech Inc
Exchange NASDAQ | Headquaters Calgary, AB, Canada | ||
IPO Launch date 1999-11-08 | CEO & Director Mr. Jared Kelly J.D., L.L.M. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://oncolyticsbiotech.com |
Full time employees 28 | Website https://oncolyticsbiotech.com | ||
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.